September 25, 2020 -- Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's COVID-19 vaccine candidate.
Under the agreement, Par Sterile, a subsidiary of Endo International, has begun production of the NVX-CoV2373 final drug candidate, with initial batches to be used in Novavax's phase III clinical trial in the U.S. Par Sterile will also fill-finish vaccine intended for commercial distribution in the U.S.
NVX-CoV2373 is currently in multiple phase II clinical trials to evaluate safety and immunogenicity. Interim data is expected before the end of 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
Financial and other terms of the agreement were not disclosed.
Copyright © 2020 scienceboard.net